CD8A and neoplasm: Furthermore, the anti-tumor properties of IL-15, attributed to its capacity to support the survival, proliferation, and effector functions of NK cells and CD8+ CTLs, have been substantiated in both preclinical models and clinical trials involving patients with RMS [68].